Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic ...

Despite advancements in melanoma therapy, the prognosis remains unfavorable for many patients. The proteasome inhibitor MG132 has shown therapeutic potential through pathway regulation, yet its ...